These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 35459264)

  • 1. Fusion protein-driven IGF-IR/PI3K/AKT signals deregulate Hippo pathway promoting oncogenic cooperation of YAP1 and FUS-DDIT3 in myxoid liposarcoma.
    Berthold R; Isfort I; Erkut C; Heinst L; Grünewald I; Wardelmann E; Kindler T; Åman P; Grünewald TGP; Cidre-Aranaz F; Trautmann M; Fröhling S; Scholl C; Hartmann W
    Oncogenesis; 2022 Apr; 11(1):20. PubMed ID: 35459264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FUS-DDIT3 Fusion Protein-Driven IGF-IR Signaling is a Therapeutic Target in Myxoid Liposarcoma.
    Trautmann M; Menzel J; Bertling C; Cyra M; Isfort I; Steinestel K; Elges S; Grünewald I; Altvater B; Rossig C; Fröhling S; Hafner S; Simmet T; Åman P; Wardelmann E; Huss S; Hartmann W
    Clin Cancer Res; 2017 Oct; 23(20):6227-6238. PubMed ID: 28637688
    [No Abstract]   [Full Text] [Related]  

  • 3. Requirement for YAP1 signaling in myxoid liposarcoma.
    Trautmann M; Cheng YY; Jensen P; Azoitei N; Brunner I; Hüllein J; Slabicki M; Isfort I; Cyra M; Berthold R; Wardelmann E; Huss S; Altvater B; Rossig C; Hafner S; Simmet T; Ståhlberg A; Åman P; Zenz T; Lange U; Kindler T; Scholl C; Hartmann W; Fröhling S
    EMBO Mol Med; 2019 May; 11(5):. PubMed ID: 30898787
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The myxoid/round cell liposarcoma fusion oncogene FUS-DDIT3 and the normal DDIT3 induce a liposarcoma phenotype in transfected human fibrosarcoma cells.
    Engström K; Willén H; Kåbjörn-Gustafsson C; Andersson C; Olsson M; Göransson M; Järnum S; Olofsson A; Warnhammar E; Aman P
    Am J Pathol; 2006 May; 168(5):1642-53. PubMed ID: 16651630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nuclear expression of FLT1 and its ligand PGF in FUS-DDIT3 carrying myxoid liposarcomas suggests the existence of an intracrine signaling loop.
    Andersson MK; Göransson M; Olofsson A; Andersson C; Aman P
    BMC Cancer; 2010 Jun; 10():249. PubMed ID: 20515481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of inhibitors regulating cell proliferation and FUS-DDIT3 expression in myxoid liposarcoma using combined DNA, mRNA, and protein analyses.
    Svec D; Dolatabadi S; Thomsen C; Cordes N; Shannon M; Fitzpatrick P; Landberg G; Åman P; Ståhlberg A
    Lab Invest; 2018 Jul; 98(7):957-967. PubMed ID: 29588491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Deciphering the role of FUS::DDIT3 expression and tumor microenvironment in myxoid liposarcoma development.
    Ranji P; Jonasson E; Andersson L; Filges S; Luna Santamaría M; Vannas C; Dolatabadi S; Gustafsson A; Myklebost O; Håkansson J; Fagman H; Landberg G; Åman P; Ståhlberg A
    J Transl Med; 2024 Apr; 22(1):389. PubMed ID: 38671504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphatidylinositol-3-kinase (PI3K)/Akt Signaling is Functionally Essential in Myxoid Liposarcoma.
    Trautmann M; Cyra M; Isfort I; Jeiler B; Krüger A; Grünewald I; Steinestel K; Altvater B; Rossig C; Hafner S; Simmet T; Becker J; Åman P; Wardelmann E; Huss S; Hartmann W
    Mol Cancer Ther; 2019 Apr; 18(4):834-844. PubMed ID: 30787173
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FUS-DDIT3 Fusion Oncoprotein Expression Affects JAK-STAT Signaling in Myxoid Liposarcoma.
    Dolatabadi S; Jonasson E; Andersson L; Luna Santamaría M; Lindén M; Österlund T; Åman P; Ståhlberg A
    Front Oncol; 2022; 12():816894. PubMed ID: 35186752
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The myxoid liposarcoma FUS-DDIT3 fusion oncoprotein deregulates NF-kappaB target genes by interaction with NFKBIZ.
    Göransson M; Andersson MK; Forni C; Ståhlberg A; Andersson C; Olofsson A; Mantovani R; Aman P
    Oncogene; 2009 Jan; 28(2):270-8. PubMed ID: 18850010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulatory mechanisms, expression levels and proliferation effects of the FUS-DDIT3 fusion oncogene in liposarcoma.
    Åman P; Dolatabadi S; Svec D; Jonasson E; Safavi S; Andersson D; Grundevik P; Thomsen C; Ståhlberg A
    J Pathol; 2016 Apr; 238(5):689-99. PubMed ID: 26865464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FUS-DDIT3 prevents the development of adipocytic precursors in liposarcoma by repressing PPARgamma and C/EBPalpha and activating eIF4E.
    Pérez-Mancera PA; Bermejo-Rodríguez C; Sánchez-Martín M; Abollo-Jiménez F; Pintado B; Sánchez-García I
    PLoS One; 2008 Jul; 3(7):e2569. PubMed ID: 18596980
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The FUS::DDIT3 fusion oncoprotein inhibits BAF complex targeting and activity in myxoid liposarcoma.
    Zullow HJ; Sankar A; Ingram DR; Samé Guerra DD; D'Avino AR; Collings CK; Lazcano R; Wang WL; Liang Y; Qi J; Lazar AJ; Kadoch C
    Mol Cell; 2022 May; 82(9):1737-1750.e8. PubMed ID: 35390276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fat-specific FUS-DDIT3-transgenic mice establish PPARgamma inactivation is required to liposarcoma development.
    Pérez-Mancera PA; Vicente-Dueñas C; González-Herrero I; Sánchez-Martín M; Flores-Corral T; Sánchez-García I
    Carcinogenesis; 2007 Oct; 28(10):2069-73. PubMed ID: 17468515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The FUS-DDIT3 Interactome in Myxoid Liposarcoma.
    Yu JSE; Colborne S; Hughes CS; Morin GB; Nielsen TO
    Neoplasia; 2019 Aug; 21(8):740-751. PubMed ID: 31220736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myxoid liposarcoma FUS-DDIT3 fusion oncogene induces C/EBP beta-mediated interleukin 6 expression.
    Göransson M; Elias E; Ståhlberg A; Olofsson A; Andersson C; Aman P
    Int J Cancer; 2005 Jul; 115(4):556-60. PubMed ID: 15688424
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Myxoid liposarcoma-associated EWSR1-DDIT3 selectively represses osteoblastic and chondrocytic transcription in multipotent mesenchymal cells.
    Suzuki K; Matsui Y; Higashimoto M; Kawaguchi Y; Seki S; Motomura H; Hori T; Yahara Y; Kanamori M; Kimura T
    PLoS One; 2012; 7(5):e36682. PubMed ID: 22570737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. DDIT3/CHOP and the sarcoma fusion oncoprotein FUS-DDIT3/TLS-CHOP bind cyclin-dependent kinase 2.
    Bento C; Andersson MK; Aman P
    BMC Cell Biol; 2009 Dec; 10():89. PubMed ID: 20017906
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of DOL54 is not restricted to myxoid liposarcomas with the FUS-DDIT3 chimera but is found in various sarcomas.
    Panagopoulos I; Mertens F; Isaksson M; Mandahl N
    Oncol Rep; 2004 Jul; 12(1):107-10. PubMed ID: 15201968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of myxoid liposarcoma-associated FUS-DDIT3 rearrangement variants including a newly identified breakpoint using an optimized RT-PCR assay.
    Powers MP; Wang WL; Hernandez VS; Patel KS; Lev DC; Lazar AJ; López-Terrada DH
    Mod Pathol; 2010 Oct; 23(10):1307-15. PubMed ID: 20581806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.